Louise Tofts

Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial

Ravi Savarirayan, Louise Tofts, Melita Irving et al. · The Lancet · 2020 · 198 citations

Medicine, Pediatrics, Pharmacotherapy +2

Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

Ravi Savarirayan, Louise Tofts, Melita Irving et al. · Genetics in Medicine · 2021 · 99 citations · Full text

Medicine, Orthopedic Surgery, Pharmacotherapy +10

Quality of life prediction in children with joint hypermobility syndrome

Verity Pacey, Louise Tofts, Roger Adams et al. · Journal of Paediatrics and Child Health · 2015 · 74 citations

Pharmacy, Child Health, Pediatrics +17

The natural history of children with joint hypermobility syndrome and Ehlers–Danlos hypermobility type: a longitudinal cohort study

Mark Scheper, Lesley L. Nicholson, Roger Adams et al. · Lara D. Veeken · 2017 · 65 citations · Full text

Medicine, Child Health, Pediatrics +16

Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial

Ravi Savarirayan, William R. Wilcox, Paul Harmatz et al. · The Lancet Child & Adolescent Health · 2023 · 64 citations

Pharmacy, Pediatrics, Pharmacotherapy +2